These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 31725651)

  • 61. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
    Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
    Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Impact of NAFLD on the outcome of patients with chronic hepatitis B in Asia.
    Yang M; Wei L
    Liver Int; 2022 Aug; 42(9):1981-1990. PubMed ID: 35373500
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Thyroid-stimulating hormone is associated with nonalcoholic steatohepatitis in patients with chronic hepatitis B.
    Liu L; Li P; Mi Y; Liu Y; Liu Y; Zhang P
    Medicine (Baltimore); 2019 Nov; 98(46):e17945. PubMed ID: 31725651
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Non-alcoholic fatty liver disease and thyroid dysfunction: a systematic review.
    Eshraghian A; Hamidian Jahromi A
    World J Gastroenterol; 2014 Jul; 20(25):8102-9. PubMed ID: 25009382
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].
    Kim SK; Kim KI; Kim SR
    Yakugaku Zasshi; 2019; 139(9):1147-1153. PubMed ID: 31474630
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The Effects of Hepatic Steatosis on the Natural History of HBV Infection.
    Suliman I; Abdelgelil N; Kassamali F; Hassanein TI
    Clin Liver Dis; 2019 Aug; 23(3):433-450. PubMed ID: 31266618
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease?
    Paschos P; Athyros VG; Tsimperidis A; Katsoula A; Grammatikos N; Giouleme O
    Curr Vasc Pharmacol; 2018; 16(3):269-275. PubMed ID: 28676018
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis.
    Haga Y; Kanda T; Sasaki R; Nakamura M; Nakamoto S; Yokosuka O
    World J Gastroenterol; 2015 Dec; 21(46):12989-95. PubMed ID: 26675364
    [TBL] [Abstract][Full Text] [Related]  

  • 70.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 71.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 72.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 4.